Rhamnetin has been reported to inhibit Notch-1 signaling pathway and P-gp protein expression and enhances the performance of adriamycin, etoposide, paclitaxel and sorafenib in MDR hepatocellular carcinoma cells (HepG2/ADR) [164]. Here, PGP is linked to hepatocellular carcinoma.